Is Neogen (NEOG) overvalued or fairly valued?

MarketChacha shows Neogen's valuation in context — a forward P/E of about 32.7, a price-to-book of about 1.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Neogen's revenue?

Neogen reported revenue of $894.7M for FY2025, with net profit of $-1.1B, per official filings.

What is the share price of Neogen (NEOG)?

Neogen last traded at $9.82 (-1.2% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Neogen

NEOG · NYSE · Healthcare · United States

$9.82-1.2%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:34 PM

Snapshot

TickerNEOG

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees2,974

HeadquartersLansing, United States

Market cap$2.1B

P/B1.0

Volume637.7K

Websitewww.neogen.com

Filings tracked4

About Neogen

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and unintended substances in human food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides software systems that help testers analyze and store results; natural toxin tests; rapid sanitation tests; culture and prepared media products; filter tests for microbial analysis of water; sample collection products; and food safety analysis laboratory services. This segment sells its products to the milling and grain, meat and poultry, ready-to-eat, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. Its Animal Safety segment provides reagents and test kits for use in immunoassay production, forensic and animal toxicology, and life science research, as well as colorimetric and chemiluminescent substrates; veterinary instruments and disposables; animal care and other products, including digestive aids and nutritional supplements; rodent and insect control products, and disinfectants; and genomics services, such as DNA genotyping, sequencing, and trait analysis for livestock and companion animals. This segment sells its products to companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.9%
Institutions99.1%
Public & other0.0%

401 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.14.99%
Vanguard Portfolio Management LLC5.90%
T. Rowe Price Investment Management, Inc.4.67%
Vanguard Capital Management LLC4.39%
Dimensional Fund Advisors LP4.20%
ING Groep N.V.4.09%
State Street Corporation3.95%
Mackenzie Financial Corporation3.58%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Margin has compressed by about 119.3 points over the period — profitability is trending down.

Net margin trend-2.8% → -122.1%

Margin has compressed by about 119.3 points over the period — profitability is trending down.

Return on equity-52.7%

Latest ROE of -52.7% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $204.7M · EPS 0.05

Est. earnings growth +25.0%

Next fiscal year

Rev $849.1M · EPS 0.30

Est. earnings growth -18.9%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$4.5652-wk range$11.43

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$2.1B

Day change

-1.2%

Fwd P/E

32.7

P/B

1.0

Beta

1.79

Revenue (FY2025)

$894.7M

Net margin

-122.1%

ROE

-52.7%

Revenue CAGR (2y)

+4.3%

EPS (FY2025)

-5.03

Net profit (FY2025)

$-1.1B

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about NEOG

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$894.7M	$-1.1B	-5.03	-122.1%	-52.7%
FY2024	$924.2M	$-9.4M	-0.04	-1.0%	-0.3%
FY2023	$822.4M	$-22.9M	-0.12	-2.8%	-0.7%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$211.2M	$-17.0M	-0.08	-8.0%
2025Q4	$224.7M	$-15.9M	-0.07	-7.1%
2025Q3	$209.2M	$36.3M	0.17	17.4%
2025Q1	$221.0M	$-10.9M	-0.05	-4.9%
2024Q4	$231.3M	$-456.3M	-2.10	-197.3%
2024Q3	$217.0M	$-12.6M	-0.06	-5.8%
2024Q1	$228.8M	$-2.0M	-0.01	-0.9%
2023Q4	$229.6M	$-3.5M	-0.02	-1.5%
2023Q3	$229.0M	$1.5M	0.01	0.7%
2023Q1	$218.3M	$8.2M	0.04	3.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Reg FD disclosure, Exhibits
SEC4/20/2026material
8-K — Results of operations, Exhibits
SEC4/9/2026material
10-Q filing
SEC4/9/2026
8-K — Executive/director change
SEC3/30/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.